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Background: Scrutiny over pharmaceutical expenditure is increasing leading to multiple
reforms. This includes Austria with measures to lower generic prices and enhance their
utilization. However the situation for newer antidepressants and atypical antipsychotic med-
icines (AAPs) is different to PPIs, statins, and renin-angiotensin inhibitor drugs with greater
tailoring of therapy and no wish to switch products in stable patients. Authorities wel-
come generics though given the high costs particularly of single-sourced AAPs. Objective:
Assess (a) changes in utilization of venlafaxine versus other newer antidepressants before
and after availability of generics, (b) utilization of generic versus originator venlafaxine,
(c) price reductions of venlafaxine over time and their influence on total expenditure, (d)
utilization of risperidone versus other AAPs, (e) suggest potential additional reforms that
could be introduced if pertinent to further enhance the use of generics. Methodology:
A quasi-experimental study design with a segmented time series and an observational
study. Utilization measured in defined daily doses (DDDs) and total expenditure per DDD
and over time. Results: No appreciable changes in the utilization of venlafaxine and risperi-
done after generics. The reduction in expenditure/DDD for venlafaxine decreased overall
expenditure on newer antidepressants by 5% by the end of the study versus just before
generics despite a 37% increase in utilization. Expenditure will further decrease if reduced
prescribing of duloxetine. Conclusion: Depression, schizophrenia, and bipolar diseases are
complex diseases. As a result, specific measures are needed to encourage the prescribing
of generic risperidone and venlafaxine when multiple choices are appropriate. Authorities
cannot rely on a “Hawthorne” effect between classes to enhance the use of generics. Mea-
sures may include prescribing restrictions for duloxetine. No specific measures planned
for AAPs with more multiple-sourced AAPs becoming available.
Keywords:Austria, antidepressants, atypical antipsychotics, drug utilization studies, generics, risperidone, reforms,
schizophrenia
BACKGROUND
GENERAL
Scrutiny on pharmaceutical expenditure has intensified across
Europe with its growth outstripping other components of ambu-
latory care, resulting in pharmaceutical expenditure becoming the
largest or equaling the largest cost component in ambulatory care
(Wettermark et al., 2008; Godman et al., 2008a, 2009a, 2010a,
2012a; Coma et al., 2009; Sermet et al., 2010; Voncina et al., 2011).
This growth is set to continue unless addressed, driven by well
known factors including changing demographics, rising patient
expectations, strict clinical targets, and the continued launch of
new premium priced medicines (Garattini et al., 2008; Wettermark
et al., 2008; Godman et al., 2008a, 2009a, 2010a, 2012a; Coma et al.,
2009; Sermet et al., 2010; Voncina et al., 2011).
These concerns have resulted in multiple reforms being insti-
gated among countries to contain costs without compromising the
quality of care (Godman et al., 2008a,b, 2009a,b, 2010b, 2011a,b,
2012b; Coma et al., 2009; Norman et al., 2009; Wettermark et al.,
2009; McGinn et al., 2010; Sermet et al., 2010; Gustafsson et al.,
2011; Voncina et al., 2011; Bennie et al., 2012). Austria is no excep-
tion. Multiple measures and initiatives introduced in Austria for
existing medicines include pricing regulations for generics and
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originators once multiple-sourced products are available. Under
these initiatives, the price of the third generic has to be at least
60% below single-sourced prices to be reimbursed (Godman et al.,
2008a, 2009c, 2010a,c, 2011a). This price also establishes the reim-
bursed price for the originator (Godman et al., 2008a, 2009c,
2010a,c,2011a). Thereafter,market forces act to obtain lower prices
for successive branded generics. These include physician IT sys-
tems highlighting the cheapest multiple-sourced product, which
build on quarterly information sent to physicians, physicians’ pre-
scribing costs benchmarked against each other coupled with finan-
cial incentives to prescribe the cheapest multiple-sourced product,
as well as quality circles among physicians with the objective to
increase the prescribing of generics versus originators (Godman
et al., 2008a, 2009c, 2010a,c, 2012a; Spiegel et al., 2012).
These multiple measures helped increase prescribing efficiency
in drug classes [Anatomical Therapeutic Chemical Classification –
ATC – Level 4; World Health Organization (WHO), 2003] where
the products are seen as essentially similar in all or nearly all
patients [Godman et al., 2008b, 2009a,c, 2010c, 2011a,b, 2012b;
Voncina et al., 2011; McGinn et al., 2010; Gustafsson et al., 2011;
Bennie et al., 2012]. Prescribing efficiency in this situation is
defined as utilization growing at a faster rate than expenditure,
with outcomes seen as similar between products. Pertinent drug
classes include the proton pump inhibitors (PPIs), statins, and
renin-angiotensin inhibitor drugs (Godman et al., 2009c, 2010c,
2011b, 2012b; Martikainen et al., 2010; McGinn et al., 2010;
Gustafsson et al., 2011; Voncina et al., 2011; Bennie et al., 2012).
The various measures, with their different intensities, resulted in
the following outcomes in Austria (Godman et al., 2009c, 2010c,
2012b; Voncina et al., 2011):
• PPIs – utilization increased (Defined Daily Doses – DDDs) 3.6-
fold between 2001 and 2007 (DDDs) but total expenditure only
increased 2.1-fold
• Statins – utilization increased approximately 2.4-fold (DDDs)
between 2001 and 2007 but there was a 3% decrease in total
expenditure
• Angiotensin Converting Enzyme Inhibitors (ACEIs) and
Angiotensin Receptor Blockers (ARBs) – utilization increased
69% between 2001 and 2007, with total expenditure increasing
only 23%.
ANTIDEPRESSANTS
Newer antidepressants, including the dual acting antidepressants
venlafaxine and mirtazapine, have also lost their patents during
the past decade in Austria. Venlafaxine and mirtazapine are typi-
cally prescribed second line after the Selective Serotonin Re-uptake
Inhibitors (SSRIs) with their increased effectiveness over the SSRIs
(Yu-Isenberg et al., 2004; Baldomero et al., 2005; Agüera-Ortiz and
Ramos Garcia, 2006; Cipriani et al., 2009). Among the newer anti-
depressants, duloxetine and reboxetine appear to be less effective
than venlafaxine and mirtazapine (Cipriani et al., 2009).
Venlafaxine in Austria now includes generic immediate release
(IR) and extended release (ER) formulations from May 2009. ER
venlafaxine was launched to reduce possible side-effects associ-
ated with IR venlafaxine (Yu-Isenberg et al., 2004; Baldomero et al.,
2005; Agüera-Ortiz and Ramos Garcia, 2006). Consequently, there
should be an opportunity to save resources with the instigation of
various measures to lower the prices of generics and the origina-
tor once multiple-sourced products become available as well as
encourage their prescribing.
However unlike the PPIs, statins and renin-angiotensin
inhibitor drugs, newer antidepressants should not be considered
as a single class as there are differences between them both in
terms of their effectiveness and side-effects (Cipriani et al., 2009).
In view of this, it is acknowledged that patients should not be
switched between therapies if they are responding to a particular
antidepressant.
There is no reason though why patients should not be pre-
scribed a multiple sourced antidepressant when suitable choices
are available. This is especially the case when physicians are
being encouraged through a variety of measures to preferentially
prescribe generics (Godman et al., 2008a).
ANTIPSYCHOTICS
The utilization of atypical antipsychotic drugs has also been
increasing in recent years for the management of schizophrenia
and bipolar disorders (Knapp et al., 2005; Mirandola et al., 2006;
NICE, 2008; Crystal et al., 2009; Wladysiuk et al., 2011). As a result
of their increased prescribing, worldwide sales of atypical antipsy-
chotic drugs were over $US5bn per year in the early 2000s, reaching
$14.6bn in the US alone in 2009 (Andretta et al., 2005; Wladysiuk
et al., 2011; Leslie and Rosenheck, 2012).
The increased prescribing of atypical antipsychotic medicines
(AAPs) appears to have been driven by meta-analyses and other
studies suggesting greater efficacy and functional recovery, as well
as lower side-effects than typical antipsychotics and other drugs
(Mond et al., 2003; Knapp et al., 2005; Leucht et al., 2009; Depart-
ment of Justice settlement agreement, 2010; Alexander et al., 2011;
Kishimoto et al., 2011; Fisk et al., 2012). These clinical improve-
ments resulted in reports of improved compliance and persistence
for atypical antipsychotics, although others have not seen this in
practice (Taylor et al., 2003; Valenstein et al., 2004; Ren et al.,
2006). As a result, in June 2002, the National Institute for Health
and Clinical Excellence (NICE) in the UK recommended the use
of atypical (newer) oral antipsychotic drugs in people with newly
diagnosed schizophrenia and those currently taking typical (older)
antipsychotics where their symptoms are being controlled but have
problems with side-effects (Walley, 2004). NICE recently updated
its guidance for patients with newly diagnosed schizophrenia
offered oral antipsychotic medication (NICE, 2009), stating that
healthcare professionals should “provide information and discuss
the benefits and side-effect profile of each drug with the service user.
The choice of drug should be made by the service user and healthcare
professional together, considering:
• the relative potential of individual antipsychotic drugs to cause
extrapyramidal side-effects (including akathisia), metabolic side-
effects (including weight gain), and other side-effects (including
unpleasant subjective experiences)
• the views of the carer where the service user agrees.”
However, there have been concerns about the quality of the evi-
dence and the extent of the differences in daily practice with
the effectiveness of typical versus atypical antipsychotics (Walley,
2004). There has also been growing criticism that high-potency
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haloperidol (typical antipsychotic) was used as a comparator in the
studies with second generation (atypical antipsychotics) thereby
biasing the results as likely to be associated with a high rate of
extrapyramidal side-effects, and only a limited number of stud-
ies used medium-potency first generation (typical) antipsychotics
as the comparator (Leucht et al., 2003; Tyrer and Kendall, 2009).
Alongside this, greater levels of side-effects such as weight gain,
hyperlipidemia, and Type 2 diabetes with atypical antipsychotics
(Andretta et al., 2005; Gardner et al., 2005; NICE, 2009; Tyrer and
Kendall, 2009; Wladysiuk et al., 2011). In addition, the risk of
QT prolongation and subsequent arrhythmia-related events, i.e.,
Torsade de Pointes (TdP) and Sudden Cardiac Death, is increas-
ingly seen as an important safety aspect to consider when atypical
antipsychotic drugs are being prescribed (Titier et al., 2005; Had-
dad and Sharma, 2007). In the past, atypical antipsychotics have
been perceived as generally having a favorable cardiac safety profile
compared with typical antipsychotic drugs. However, these beliefs
have been undermined by a recent cohort study finding a dose-
dependent increased risk of sudden cardiac deaths among current
users of atypical antipsychotic drugs (Ray et al., 2009), further cor-
roborated by different case series (Vieweg et al., 2009) as well as
pharmacovigilance analyses (Poluzzi et al., 2009; Meyer-Massetti
et al., 2011), showing similar reporting ratios between typical and
atypical antipsychotic drugs in clinical practice. Tiihonen et al.
(2009) have also raised concerns regarding the prescribing of que-
tiapine. In a recent study, the highest risk of mortality in patients
with schizophrenia prescribed atypical antipsychotic drugs was
with quetiapine, and the lowest was with clozapine. Haloperidol
and risperidone had slightly lower adjusted hazard ratios than
quetiapine (Tiihonen et al., 2009).
These debates have continued with the publication of the vari-
ous findings from the Clinical Antipsychotic Trials of Intervention
Effectiveness (CATIE) study in the US showing limited differences
in effectiveness between the various antipsychotics, although this
is not without criticism (Lieberman et al., 2005; Lieberman and
Stroup, 2011; Wladysiuk et al., 2011; Berkowitz et al., 2012). The
studies do show though that the variation in the effectiveness of the
different AAPs can be substantial between individual patients, and
that side-effects can also differ between different AAPs (Lieberman
and Stroup, 2011). Consequently, “treatments for schizophrenia
must be individualized”(Lieberman and Stroup, 2011). These find-
ings are endorsed by Cochrane Collaboration reviews and other
studies suggesting tentatively that olanzapine may be somewhat
more efficacious than some other second generation antipsychotic
drugs although concerns with high drop-out rates in the studies,
with mixed results with risperidone (Hargreaves and Gibson, 2005;
Heres et al., 2006; Komossa et al., 2010, 2011).
Other authors believed the modest gains with atypical antipsy-
chotic drugs that have reported do not adequately reflect the
improvements in quality of life perceived by patients, clinicians,
or carers (Magnus et al., 2005), leading to increased use. Conse-
quently, it is likely there will continue to be growing utilization
of atypical antipsychotic medicines (Knapp et al., 2005; Miran-
dola et al., 2006; NICE, 2008; Crystal et al., 2009; Wladysiuk et al.,
2011).
As a result, the availability of generic atypical antipsychotic
medicines at low prices should be welcomed by health authorities
and health insurance agencies with growing resource pressures.
The first atypical antipsychotic drug to become available among
Western countries was clozapine, with published studies showing
no difference in outcomes between the originator and gener-
ics in practice once the bioavailability problem with the first
generic clozapine in the US had been resolved (Bazire and Bur-
ton, 2004; Healy et al., 2005; Alessi-Severini et al., 2006; Paton,
2006; Araszkiewicz et al., 2008). More recently, generic olanza-
pine and generic risperidone became available among European
countries. Again, there appears to be no patient issues in practice
(Araszkiewicz et al., 2008; Khorana et al., 2011; Wladysiuk et al.,
2011; Correl and Carbon, 2012), although some authors are more
cautious (Desmarais et al., 2011; Correl and Carbon, 2012).
However, it is recognized that schizophrenia and other con-
ditions such as bipolar disorders are complex diseases to treat.
In addition, atypical antipsychotic drugs should not be consid-
ered as one class (Heres et al., 2006; NICE, 2009; Lieberman and
Stroup, 2011). As a result, greater necessity for tailoring treatments
depending on the patient and their characteristics, including cur-
rent co-morbidities, having considered the safety profile of each
drug including its pharmacokinetic profile (NICE, 2009; Poluzzi
et al., 2009; Ray et al., 2009; Tiihonen et al., 2009; Vieweg et al.,
2009; Lieberman and Stroup, 2011; Meyer-Massetti et al., 2011). In
addition, switching patients between treatments should never be
considered if they are stable on a particular atypical antipsychotic
drug.
OBJECTIVES
The availability of oral generic newer antidepressants as well as
atypical antipsychotic drugs in addition to clozapine should in
theory lead to their increased prescribing. However, this remains
to be seen due to the complexities of treating depression, schiz-
ophrenia, and other mental health conditions compared with
treating stomach related acid disorders, hypercholesterolemia or
hypertension.
Consequently, the objectives of this paper are to assess (a)
changes in the utilization of venlafaxine versus other newer anti-
depressants before and after the availability of generic IR and ER
formulations, (b) utilization of generic versus originator venlafax-
ine, (c) price reductions of venlafaxine IR and ER over time and
the subsequent influence on total expenditure of antidepressants
over time, (d) the utilization of risperidone versus other atypi-
cal antipsychotic drugs over time following generic availability,
(e) suggest potential additional reforms if pertinent that could
be introduced in Austria to further enhance the prescribing of
multiple-sourced antidepressants and atypical antipsychotic drugs
when multiple drug choices are available and appropriate.
METHODOLOGY
Two methodologies were utilized. The first involves a quasi-
experimental study design with a segmented time series
(Grimshaw et al., 2000; Wagner et al., 2002) to analyze ret-
rospectively monthly reimbursed prescriptions for all patients
in Austria covered by the social health insurance system pre-
scribed at least one newer antidepressant including mirtazap-
ine (N06AX11), venlafaxine (N06AX16), reboxetine (N06AX18);
duloxetine (N06AX21) and agomelatine [N06AX22; World Health
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Organization (WHO), 2012] from May 2007, i.e., 24 months
before the availability of generic venlafaxine in May 2009 (IR
and ER) to August 2011, 27 months after generic venlafaxine.
Desvenlafaxine (N06AX23) was never reimbursed in Austria. The
data source was the internal data warehouse of the HVB (BIG),
Cube HMSTAT, based on the“maschinelle Heilmittelabrechnung,”
which covers approximately 98% of the Austrian population
(Godman et al., 2009c, 2010c).
The second study is a retrospective observational study of the
same population dispensed at least one atypical antipsychotic drug
[N05AH03–05, N05AL05, N05AX08, 11–13; World Health Orga-
nization (WHO), 2003] between 2005, i.e., 1 year after generic
risperidone became available, to 2010, 6 years after generic risperi-
done became available. Clozapine was not included in the analysis
as it is reserved for resistant patients due to its side-effect pro-
file (Healy et al., 2005; Paton, 2006; Leucht et al., 2009, 2011;
Asenjo Lobos et al., 2010; Raja, 2011; Wladysiuk et al., 2011).
The data source was again the internal data warehouse of the
HVB (BIG), Cube HMSTAT, based on the “maschinelle Heilmit-
telabrechnung,” which covers approximately 98% of the Austrian
population (Godman et al., 2009c, 2010c). No analysis of expen-
diture was undertaken as generic risperidone was already available
by 2005 and reduced expenditure for risperidone is guaranteed
given the current strict regulations governing the prices of generics
and originators in Austria once multiple sourced products become
available (Godman et al., 2008a, 2009c, 2010a,c, 2011a, 2012a).
The two methodologies were chosen to provide different data
sets, especially since generic risperidone was already available
before the study period.
Utilization was collated in terms of DDDs, with DDDs defined
as “the average maintenance dose of a drug when used in its
major indication in adults,” as this measure is recognized as
the international standard to assess utilization patterns within
and between countries [World Health Organization (WHO),
2012]. 2011 DDDs were used in line with international guid-
ance [Vlahovic-Palcevski et al., 2010; Godman et al., 2010b, 2011a;
World Health Organization (WHO), 2003, 2012].
The regression analysis for the newer antidepressants was
undertaken using the “R” methodology (R Core Team, 2012).
Using this methodology, reimbursed prescriptions were explained
by a variable “Time” with its origin in May 2009 (generic venlafax-
ine) and a variable “Inter” to model the change in slope following
the availability of generic venlafaxine.
Total costs in Euros were again used for the analysis to facil-
itate comparisons with previous studies (Godman et al., 2009c,
2010c). This is because it is difficult in practice to disaggregate
pharmacy and wholesaler mark-ups from total costs in Austria,
compounded by 20–25% of the Austrian population currently
exempt from basic co-payment. As a result, total costs provide a
more robust measure than estimating reimbursed costs using any
derived formula (Godman et al., 2009c, 2010c). Total costs are the
price paid to the pharmacy for the product including the ex-factory
price, the wholesaler, and pharmacy mark-ups but excluding VAT
(Godman et al., 2009c, 2010c). Total expenditure per DDD was
computed for generic and originator IR and ER venlafaxine, as
well as total monthly expenditure of the newer antidepressants
over time.
There has been no allowance for inflation as we wanted to
compute the actual influence of the various policies on total
expenditure, as well as total expenditure/DDD, over time for the
various antidepressants. In addition, the tendency of authorities
across Europe is to cut prices of both patented (single-sourced)
drugs and generics when pharmaceutical expenditure is rising
more rapidly than target budgets (Coma et al., 2009; Sermet et al.,
2010; Godman et al., 2010b, 2011a; Garuoliene et al., 2011; Vogler
et al., 2011; Voncina et al., 2011). Alongside this, a number of Euro-
pean countries establish their initial prices for generics based on
originator pre-patent loss prices, i.e. singles-sourced prices, which
includes Austria (Godman et al., 2008a, 2009c, 2010a,c, 2011a,b,
2012a,c; Voncina et al., 2011). Consequently the use of total expen-
diture, as well as no allowance for inflation, is in line with previous
publications.
RESULTS
The utilization of newer antidepressants increased by 37% from
the launch of generic venlafaxine (IR and ER) until the end of the
study based on accumulated six monthly DDDs (Table 1).
This growth included increasing utilization of venlafaxine
(Figure 1), although there was no change in the overall utilization
pattern of venlafaxine before and after the availability of generic
IR and ER venlafaxine (Figure 1) with a probability of 0.591. This
growth in the utilization of newer antidepressants (Table 1) is prin-
cipally driven by increasing use of duloxetine in recent years, with
the utilization of both reboxetine and agomelatine remaining low
throughout the study period (Figure 1). As a result, the utilization
of venlafaxine as a % of total antidepressant utilization decreased
from 46% of all DDDs just before generic ER venlafaxine to 44%
by August 2011.
The increase in the utilization of the other antidepressants com-
bined was significant at the 0.1 level (p= 0.0843), but not at the
0.05 level (Figure 1, Table 2).
There was a 5% reduction in total expenditure of the newer
antidepressants 27 months after the availability of generic IR
and ER venlafaxine at C12.1mn (accumulated 6 months) ver-
sus C12.725mn just before generic venlafaxine (accumulated
6 month basis). This was helped by a reduction in expenditure
for venlafaxine after generic availability (Figure 2).
Table 1 | Utilization of newer antidepressants (mn DDDs) on an
accumulated six monthly basis before and after the availability of
generic venlafaxine ER (May 2009).
Months after generic venlafaxine Six monthly accumulated
data (DDDs mn)
18 months before 11,752
12 months before 12,701
6 months before 13,379
Launch generic venlafaxine 14,751
6 months after 15,804
12 months after 17,279
18 months after 18,120
24 months after 19,601
27 months after 20,238
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FIGURE 1 | Utilization pattern of newer antidepressants in DDDs before and after generic IR and ER venlafaxine (May 2009).
Table 2 | Residuals and coefficients for the change in the utilization of other antidepressants before and after generic ER venlafaxine.
RESIDUALS
Minimum First Qtr Median Third Qtr Maximum
−153307 −52437 −4846 54932 264627
Coefficients Estimate Standard error T value Significance
Intercept 1386886 26892 51.572 <0.001
Time 14276 2125 6.719 <0.001
Inter 6010 3411 1.762 0.0843
Residual standard error: 91070 on 49 degrees of freedom. Multiple R-squared: 0.901, Adjusted R-squared: 0.897. F-statistic: 223.1 on 2 and 49 DF. p-Value<2.2e−16.
The reduction in expenditure for venlafaxine was helped
by a reduction in expenditure/DDD for both IR and ER
venlafaxine once generics became available (Figure 3). Total
expenditure/DDD for generic IR venlafaxine in August 2011 was
68% below single-sourced prices (Figure 3), with a similar reduc-
tion in the price of the originator. There was a lower reduction in
expenditure/DDD for generic ER venlafaxine ER (42% reduction)
from May 2009 to August 2011.
There was increased utilization of risperidone after the avail-
ability of generic risperidone (Figure 4). However, the 81% growth
in overall atypical antipsychotic utilization from 2005 to 2010
(DDD basis) was principally driven by increasing utilization of
quetiapine and aripiprazole (Figure 4). This resulted in the utiliza-
tion of risperidone as a percentage of total atypical antipsychotic
DDDs decreasing from 32% in 2005 to 24% in 2010.
DISCUSSION AND CONCLUSION
We believe the lack of change in the utilization pattern of ven-
lafaxine after the availability of generic IR and ER venlafaxine
(Figure 1) reflects the greater complexity in treating patients
with depression than those with stomach acid related disorders,
hypercholesterolemia or hypertension with PPIs, statins, and
renin-angiotensin inhibitor drugs respectively (Godman et al.,
2009c, 2010c). Consequently, specific measures will be required
to encourage the prescribing of multiple-sourced antidepressants
when options are available to the prescribing physician. A sim-
ilar situation is seen in the management of Parkinson’s disease
where patients require add-on therapies to prolong the effective-
ness and compliance with their treatment (Brkicic et al., 2012). As
a result, there is again a need for specific demand-side measures to
change subsequent prescribing habits with greater individualiza-
tion of treatment (Brkicic et al., 2012). Consequently, authorities
cannot rely on a Hawthorne effect between classes (Holden, 2001;
Verstappen et al., 2004; Trietsch et al., 2009; Konstantinou, 2012)
especially for complex disease areas. The Hawthorne effect in stud-
ies relates to the confounding that occurs if experimenters fail to
realize how the consequences of a given subject’s performance in
one area may affect activities in another area (Parsons, 1974).
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FIGURE 2 |Total expenditure on antidepressants in Austria before and after the availability of generic ER venlafaxine (May 2009).
FIGURE 3 |Total expenditure/DDD for venlafaxine IR over time (C).
Specific measures in the case of antidepressants could
include academic detailing, prescribing guidance, and prescribing
restrictions to encourage the prescribing of multiple-sourced
antidepressants such as venlafaxine and mirtazapine where
appropriate. Prescribing restrictions have been successfully intro-
duced in Austria to limit the prescribing of atorvastatin and
rosuvastatin versus generic statins, ARBs versus ACEIs, and single-
sourced ARBs versus generic losartan (Godman et al., 2009c,
2010c, 2012b; Voncina et al., 2011; Bucsics et al., 2012). They have
also successfully been instigated in other countries, although care
is needed with follow-up to avoid disappointment (Godman et al.,
2011b, 2012b).
Prescribing restrictions are an option for duloxetine
(Figure 1) given its appreciably higher acquisition costs than
multiple-sourced venlafaxine combined with published studies
demonstrating lower effectiveness than other antidepressants
(Cipriani et al., 2009). The restrictions would limit the prescrib-
ing of duloxetine to second line after mirtazapine or venlafaxine if
there are concerns with their side-effects or effectiveness in prac-
tice. In addition intolerance to either mirtazapine or venlafaxine,
which mirrors the situation for ARBs versus ACEIs in Austria
(Godman et al., 2010c). We accept that the heterogeneous nature
of the therapeutic indications for duloxetine, including diabetic
peripheral neuropathic pain, may explain some of its increased
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FIGURE 4 | Utilization of atypical antipsychotic drugs in Austria 2005–2010 (DDDs).
utilization in recent years (Figure 1). However, it is difficult to
know the extent of prescribing in these other indications without
access to specific patient data. Prescribing restrictions have already
been introduced for duloxetine in Sweden in similar circumstances
[Cymbalta (duloxetine) receives restricted reimbursement, 2010].
As a result, providing an example for the authorities in Austria to
follow if wished.
The reduction in expenditure/DDD for IR venlafaxine over
time for both generics and the originator (Figure 3) is in line with
expectations. This reduction mirrors the 83% reduction in expen-
diture/DDD for generic losartan in Austria by August 2011 versus
single-source prices, generic ACEIs up to 77% below single-source
prices, generic omeprazole 77% below, and generic simvastatin
72% below single-source prices by the end of 2007 in Austria (God-
man et al., 2009c, 2010c). The reduction in expenditure/DDD for
venlafaxine following the availability of multiple-sourced prod-
ucts helped the authorities reduce their expenditure on newer
antidepressants in recent years. This was despite their utiliza-
tion increasing by 37% from the availability of generic IR and
ER venlafaxine to the end of the study (accumulated six monthly
basis – Table 1). However, the reduction in total expenditure would
have been greater without increasing expenditure on duloxetine in
recent months (Figure 2).
There was no appreciable change in the utilization pattern
for risperidone following the availability of generic risperidone
(Figure 4). This is similar to the situation in Belgium, Scot-
land, Spain, and Ireland with again no appreciable change in
the utilization of risperidone following the availability of generic
risperidone (Godman et al., 2012d). This may reflect the advice
from organizations such as NICE in the UK, as well as the
conclusions from the various Cochrane reviews and the CATIE
studies, that treatment with atypical antipsychotics should be
tailored to the individual (Walley, 2004; Lieberman et al., 2005;
Lieberman and Stroup, 2011; NICE, 2009; Komossa et al., 2010,
2011). Again this is unlike the situation with the PPIs, statins or
renin-angiotensin inhibitor drugs, with schizophrenia and bipolar
diseases seen as more complex to treat than acid-related stomach
disorders, hypercholesterolemia or hypertension. Consequently,
again no Hawthorne effect transferring initiatives from other
disease areas to schizophrenia or bipolar disease (Holden, 2001;
Verstappen et al., 2004; Trietsch et al., 2009; Konstantinou, 2012).
The lack of a Hawthorne effect is no doubt enhanced in this sit-
uation by lack of any desire among physicians to switch patients
between atypical antipsychotic drugs when they are stable on a
particular one. As a result, specific measures will be needed to
encourage the prescribing of multiple sourced antipsychotic drugs
when several options are available to physicians to slow down the
growth in the utilisation of single-source atypical antipsychotic
drugs (Figure 4). Specific demand-side measures could include
new guidelines highlighting the preferential prescribing of generic
atypical antipsychotic drugs first line if there are no major patient
issues or prescribing restrictions. However, no additional measures
are currently being planned by the HVB with both quetiapine and
olanzapine now available as multiple-sourced products in Austria.
This may change though with increasing recognition that there can
be limited clinical benefit of atypical antipsychotic drugs in some
patients, alongside potentially life-threatening events (Titier et al.,
2005; Maher et al., 2011), and with the possibility of new atypical
antipsychotic drugs in the future. However, this remains to be seen.
Finally, there appears to be no problems in practice with either
multiple-sourced venlafaxine (IR and ER) or oral risperidone.
However, specific research will be needed before we can make any
definitive statements.
In conclusion, depression, schizophrenia and bipolar diseases
are complex diseases to treat with physicians having no wish
to switch patients between medicines, especially when patients
are stable on a particular medicine. As a result, specific mea-
sures are needed to encourage the prescribing of multiple-
sourced antidepressants or atypical antipsychotic drugs when
several options are available and appropriate, and authorities
cannot rely on a “Hawthorne” effect between classes. Specific
measures may include guidelines or prescribing restrictions for
duloxetine, especially given concerns with its effectiveness versus
other newer antidepressants such as venlafaxine and appreciably
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higher acquisition costs. No specific measures are currently being
planned for generic atypical antipsychotic drugs in Austria with
more multiple-sourced choices becoming available. However, the
situation will be monitored.
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